OVARY

S1714: Neuropathy Trial (Observational Study)

Eligibility: Stg I,II or III primary non-small cell lung cancer, breast cancer or ovarian/fallopian tube cancer. Scheduled to receive taxane-based chemotherapy.

To develop and validate a prediction model of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens.

Learn more about the S1714 trail or call the Phoenixville Hospital Clinical Research Office at 610-983-1811.